Skip to content

Research at St Andrews

Stephen Henry Gillespie

Person

Stephen Henry Gillespie
Postal address:
School of Medicine
Medical & Biological Sciences
North Haugh
St Andrews
United Kingdom

E-mail: shg3@st-andrews.ac.uk

Web address: https://infection.st-andrews.ac.uk/

Direct phone: +44 (0)1334 461871

Research overview

Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last twenty years Stephen Gillespie has been involved in various aspects of  tuberculosis drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He is also one of the three Chief Investigators of the PanACEA consortium that is developing Europe and Africa's clinical trials capacity.

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations